"The
Report Dyslipidemia - 5EU Drug Forecast and Market Analysis to 2023
provides information on pricing, market analysis, shares, forecast,
and company profiles for key industry participants. -
MarketResearchReports.biz"
GlobalData estimates that the
total market size for the 8MM in 2013 was $15.4bn, comprised of
$11.0bn in branded drug sales (72%) and $4.4bn in generic sales
(28%). GlobalData expects that the dyslipidemia
drug market will
grow at a CAGR of 9.4% over the ten year forecast period, resulting
in a market value of $37.9bn by 2023, of which 71% will be attributed
to branded drug sales ($26.9bn) and 29% to generic drug sales
($11.0bn). The current dyslipidemia market is dominated by the
statins, the revolutionary drugs that reduce low-density lipoprotein
cholesterol (LDL-C) and that have been proven to reduce the risk of
cardiovascular events such as heart attack and stroke. Other major
lipid-modulating drugs, such as Zetia (ezetimibe), the fibrates, bile
acid sequestrants, omega-3 fish oil agents, and rare-disease
therapies comprise the remainder of the current dyslipidemia space.
The launch of the proprotein convertase subtilisin/kexin type 9
(PCSK9) biologics and the cholesteryl ester transfer protein (CETP)
inhibitors will reshape the sales landscape of the dyslipidemia
market moving forward.
As with the other markets
examined in this forecast, dyslipidemia sales in the 5EU in the 2013
base year were dominated by the statins and ezetimibe. In 2013,
statin sales contributed 64% ($1.5 billion) towards the dyslipidemia
market share in the 5EU.
Download
Sample copy of this Report at :
http://www.marketresearchreports.biz/sample/sample/825691
Scope
-
Overview of Dyslipidemia including epidemiology, etiology, symptoms,
diagnosis, pathology and treatment guidelines as well as an overview
on the competitive landscape.
-
Detailed information on the key drugs in 5EU including product
description, safety and efficacy profiles as well as a SWOT analysis.
-
Sales forecast for the top drugs in 5EU from 2013-2023.
-
Analysis of the impact of key events as well the drivers and
restraints affecting 5EU Dyslipidemia market.
Reasons to buy
-
Understand and capitalize by identifying products that are most
likely to ensure a robust return
-
Stay ahead of the competition by understanding the changing
competitive landscape for Dyslipidemia.
-
Effectively plan your M&A and partnership strategies by
identifying drugs with the most promising sales potential
-
Make more informed business decisions from insightful and in-depth
analysis of drug performance
-
Obtain sales forecast for drugs from 2013-2023 in 5EU.
Table of Contents
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 10
2 Introduction 11
2.1 Catalyst 11
2.2 Related Reports 12
2.3 Upcoming Related Reports 13
3 Disease Overview 14
3.1 Etiology and
Pathophysiology 14
3.1.1 Etiology 14
3.1.2 Pathophysiology 16
3.2 Symptoms 20
3.3 Prognosis 20
3.4 Quality of Life 20
4 Disease Management 21
4.1 Diagnosis and Treatment
Overview 21
4.1.1 Diagnosis 21
4.1.2 Treatment Guidelines and
Leading Prescribed Drugs 23
4.1.3 Clinical Practice 26
4.2 France 28
4.3 Germany 30
4.4 Italy 33
4.5 Spain 35
4.6 UK 37
5 Competitive Assessment 40
5.1 Overview 40
5.2 Product Profiles - Major
Brands 44
5.2.1 Statins 44
5.2.2 Zetia (ezetimibe) 64
5.2.3 Vytorin
(simvastatin/ezetimibe) 73
5.2.4 Liptruzet
(atorvastatin/ezetimibe) 77
5.2.5 Niaspan (niacin
extended-release) 81
5.2.6 Kynamro (mipomersen
sodium) 87
5.2.7 Juxtapid (lomitapide) 94
Follow
us on LinkedIn:
https://www.linkedin.com/company/marketresearchreports-biz
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment